Japan’s innovative life sciences sector risks falling behind global rivals, according to Economist Intelligence Unit report
- High-quality scientific publications from Japan decreased by 17% between 2015 and 2019, while China’s increased by 80% during the same period.
- Women make up only 15% of the R&D workforce, and foreign researchers account for only 5.6% of the R&D workforce in Japan vs. 28% in the US
- Investment in R&D in Japan is far below that of the US or China (US$18.1bn vs. US$179bn and US$100bn, respectively).
TOKYO, JAPAN – Media OutReach – 29 September 2020 – Medical innovation in the life sciences requires a holistic policy and market access environment that supports everything from basic science to product research and development (R&D) and, ultimately, commercialization. Though North America and Europe are historically leaders in innovation for the life sciences, Japan has been a leading contributor from Asia for decades. However, emerging life science sectors in South Korea, and more recently China, are quickly catching up after investing heavily